Race's first important asset is a chemotherapy drug called Bisantrene which was the subject of more than 40 phase II clinical studies before it was lost in a series of pharmaceutical mergers during the 1990s. Race Oncology has rediscovered Bisantrene and we plan to put this valuable drug back in the hands of clinicians to treat Leukaemia.
In the United States, Race owns two granted patents on Bisantrene and has secured Orphan Drug designation and Rare Paediatric Disease designation. Our goal is to complete clinical development and gain approval by the US FDA.
Race Oncology CEO Peter Molloy and Chair Dr Bill Garner.
Race Oncology is pleased to announce it has executed an agreement with Washington D.C –
Race Oncology is pleased to announce that it has received a letter from the FDA advising that
The chart below details the long-term survival case report of two paediatric relapsed or
Race Oncology is pleased to announce that approval has been received from the Medicines and
Race Oncology is pleased to announce a case report describing the successful use of Bisantrene
Race Oncology Non-Executive Director Dr. John Cullity speaks with Proactive Investors about the